editor
Publisher
Michael Walls
michael@accessnews.com.au
0407 783 413
Sunday, 18 February 2024 08:02
SUPPORT FOR COMMUNITY GRANTS
THE NSW Government's Open Streets program encourages councils to organize more community events by providing up to $150,000 for street closures. Aimed at easing cost-of-living pressures, the initiative supports free and safe cultural events such as markets, performances, dining, and street parties. Part of the $15M Vibrant Streets package, it aligns with Vibrancy reforms that simplify the event approval process without requiring a Development Application, significantly reducing associated costs. Applications are open from January 29, and funded events must occur by January 2025. Visit the Vibrant Streets Package website for details.
Published in
Default Set
Sunday, 18 February 2024 07:59
THE MOST POPULAR BABAY NAMES
IN 2023, Isla has been preliminarily declared the most popular girl's name, tied with 2020 favorite Amelia. Oliver returns to the top spot for boys after a one-year break, having dominated for eight consecutive years until 2022. Charlotte drops to fifth place from last year's first. Lily reemerges in seventh place, last seen in the top 10 in 2010. New additions include Leo, Henry, Luca, and Hudson. The final rankings will be confirmed in April, with registrations yet to be accounted for. Parents must register births within 60 days for legal identity access to government services.
Published in
Default Set
Sunday, 18 February 2024 07:58
PHARMACY PRESCRIBING TRIAL EXPANDS
STARTING in 2024, the NSW Government's pharmacy prescribing trial expands access to prescription medicines for specific skin conditions. Participating pharmacists can provide certain medications without a prescription after a consultation. The trial aims to ease the burden on general practitioners. From late March, pending ethics approval, impetigo and shingles treatments will be included. The initiative, which began with urinary tract infection treatment, has expanded to over 1,100 pharmacies. The skin condition treatment segment of the trial will run for 12 months, benefiting patients and improving timely access to care. More details are available on the NSW Health website.
Published in
Default Set